Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Hematologic Malignancies
Filter by Topic
Leukemia
Self-Reports of 6-Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia Unreliable
By
Phoebe Starr
Hematologic Malignancies
May 2016, Vol 7, No 4
Approximately 40% of children with acute lymphoblastic leukemia (ALL) fail to take 6-mercaptopurine (6-MP) as prescribed, and a sizable majority of parents and children with ALL overreport the intake of a critical drug for maintaining remission, according to a study reported by lead investigator Wendy Landier, PhD, RN, NP, Children’s of Alabama, Birmingham, and colleagues at ASH 2015.
Read Article
Imatinib Can Be Safely Discontinued in Patients with Deep Molecular Response
By
Chase Doyle
Hematologic Malignancies
May 2016, Vol 7, No 4
Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in patients with chronic myeloid leukemia (CML) has demonstrated that imatinib (Gleevec) can be safely discontinued in patients with a deep molecular response (ie, lasting at least 2 years). According to data presented at ASH 2015, molecular relapse was very rare after 6 months of stopping imatinib, and no relapse was reported after 2 years.
Read Article
Another Study Shows Benefit of Pediatric Regimen in Young Adults with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Hematologic Malignancies
April 2016, Vol 7, No 3
A pediatric regimen achieves superior outcomes compared with adult regimens in adolescents and young adults with acute lymphoblastic leukemia (ALL). Several studies have already shown this outcome, and a multicenter phase 2 study presented at ASH 2015 adds further confirmatory evidence in support of this approach.
Read Article
Transplant Remains Best Upfront Treatment Option in Newly Diagnosed Myeloma
By
Dana Taylor
Hematologic Malignancies
April 2016, Vol 7, No 3
The use of novel agents in multiple myeloma has led experts to question whether autologous stem-cell transplant (ASCT) is warranted upfront, or whether it can be used as effectively after patients relapse.
Read Article
CAR T-Cell Therapy Highly Active in Various Lymphomas
Hematologic Malignancies
,
Lymphoma
February 2016, Vol 7, No 1
The use of therapy with chimeric antigen receptor (CAR)-modified T-cells consistently demonstrated activity in advanced hematologic malignancies, including different types of lymphoma, in multiple trials reported at ASH 2015.
Read Article
Checkpoint Inhibitors in Lymphoma: A New Universe
By
Phoebe Starr
Hematologic Malignancies
,
Immunotherapy
,
Lymphoma
,
Personalized Medicine
February 2016, Vol 7, No 1
Immunotherapy is generating great excitement in melanoma and non-small-cell lung cancer (NSCLC). The FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying these therapies in hematologic cancers.
Read Article
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Treatment with CD19-targeted immunotherapy blinatumomab (Blincyto) as a single agent showed antileukemic activity in patients with minimal residual disease (MRD) Philadelphia chromosome (Ph)-positive B-cell precursor acute lymphoblastic leukemia (ALL) whose disease progressed after or was intolerant to a second-generation or later tyrosine kinase inhibitor (TKI). The results were presented at ASH 2015.
Read Article
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Ibrutinib (Imbruvica) significantly reduced the risk for disease progression or death compared with standard treatment with chlorambucil (Leukeran) in older (aged ≥65 years) treatment-naive patients with chronic lymphocytic leukemia (CLL). Ibrutinib achieved a 91% reduction in the risk for disease progression and an 84% reduction in the risk for death compared with chlorambucil.
Read Article
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Idelalisib (Zydelig) reduced the risk for disease progression and death when added to bendamustine (Treanda) plus rituximab (Rituxan) versus bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of a randomized, double-blind, placebo-controlled, phase 3 late-breaking trial presented at ASH 2015.
Read Article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Dose-optimized nilotinib (Tasigna) increased the rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study. According to the final results of this study presented at ASH 2015, the cumulative major molecular response rates were 70.8% by 12 months and 81.0% by 24 months in patients managed with the dose optimization strategy.
Read Article
Page 9 of 11
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma